Usefulness of Taurine in Chronic Congestive Heart Failure and Its Prospective Application

Jpn Circ J. 1992 Jan;56(1):95-9. doi: 10.1253/jcj.56.95.

Abstract

We compared the effect of oral administration of taurine (3 g/day) and coenzyme Q10 (CoQ10) (30 mg/day) in 17 patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, whose ejection fraction assessed by echocardiography was less than 50%. The changes in echocardiographic parameters produced by 6 weeks of treatment were evaluated in a double-blind fashion. In the taurine-treated group significant treatment effect was observed on systolic left ventricular function after 6 weeks. Such an effect was not observed in the CoQ10-treated group.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Cardiomyopathy, Dilated / complications
  • Chronic Disease
  • Coenzymes
  • Coronary Disease / complications
  • Double-Blind Method
  • Drug Evaluation
  • Echocardiography
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Heart Failure / physiopathology
  • Humans
  • Male
  • Stroke Volume
  • Taurine / administration & dosage
  • Taurine / therapeutic use*
  • Ubiquinone / analogs & derivatives
  • Ubiquinone / therapeutic use
  • Ventricular Function, Left / drug effects

Substances

  • Coenzymes
  • Ubiquinone
  • Taurine
  • coenzyme Q10